Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd (No 2)

Link copied
Case Copied 34 min read

FEDERAL COURT OF AUSTRALIA

Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd (No 2)
[2019] FCA 657

File number(s): NSD 2149 of 2016
Judge(s): BURLEY J
Date of judgment: 13 May 2019
Catchwords:

COSTS – application for preliminary discovery pursuant to r 7.23 of the Federal Court Rules 2011 (Cth) – where prospective applicant was substantially successful in application which was contested by prospective respondents – discretion in making costs orders pursuant to s 43(2) of Federal Court of Australia Act1976 (Cth) to be exercised judicially – contingent costs order not appropriate – prospective applicant awarded 50% of its costs

PRACTICE AND PROCEDURE – preliminary discovery – confidentiality  – principles to be applied – restrictions imposed

Legislation:

Federal Court of Australia Act 1976 (Cth) s 37AF, 37M, 37N

Federal Court Rules 2011 (Cth) r 7.23

Patents Act 1990 (Cth) s 97(3)

Cases cited:

 Aristocrat Technologies Australia Pty Limited v Ainsworth Game Technology Limited (No 2) [2019] FCA 511

C7 Pty Ltd v Foxtel Management Pty Ltd [2001] FCA 1864

Cappuccio v Australia & New Zealand Banking Group Ltd [1999] FCA 1188

Cobankara v Australia and New Zealand Banking Group Ltd [2017] FCA 419

Conor Medsystems Inc v University of British Columbia (No 4) [2007] FCA 324

Dallas Buyers Club LLC v iiNet Limited (No 3) [2015] FCA 422; 327 ALR 695

E D Oates Pty Ltd v Edgar Edmondson Imports [2012] FCA 356

Gearhart United Pty Ltd v Omni Oil Technologies (Asia) SDN BHD (No 2) [2010] FCA 558

Glencore International AG v Selwyn Mines Limited [2005] FCA 801; 223 ALR 238

Harman v Secretary of State for the Home Department [1983] 1 AC 280; 1 All ER 532

Hearne v Street [2008] HCA 36; 235 CLR 125

J & A Vaughan Super Pty Ltd v Becton Property Group Limited [2013] FCA 340

ObjectiVision Pty Ltd v Visionsearch Pty Ltd (No 3) [2015] FCA 304

Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCA 285

Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCAFC 193; 257 FCR 62

Procter v Kalivis (No 3) [2010] FCA 1194

Sabre Corporation Pty ltd v Russ Kalvin’s Hair Care Company [1993] FCA 841; 124 ALR 400

SmithKline Beecham plc v Alphapharm Pty Ltd [2001] FCA 271

Steffen v ANZ Banking Group [2009] NSWSC 883

Date of hearing: 3 April 2019
Date of last submissions: 25 April 2019
Registry: New South Wales
Division: General Division
National Practice Area: Intellectual Property
Sub-area: Patents and Associated Statutes
Category: Catchwords
Number of paragraphs: 32
Counsel for the Prospective Applicants: Mr D. Shavin QC with Mr C. Dimitriadis SC and Ms C. Cochrane
Solicitor for the Prospective Applicants: DLA Piper Australia
Counsel for the Prospective Respondent: Mr B. Caine QC with Mr J. S. Cooke and Mr D. B. Larish
Solicitor for the Prospective Respondent: Ashurst Australia

ORDERS

NSD 2149 of 2016
BETWEEN:

PFIZER IRELAND PHARMACEUTICALS

First Prospective Applicant

WYETH LLC

Second Prospective Applicant

PFIZER AUSTRALIA PTY…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2019] FCA 657
Decision Date

CaseChat Overview and Summary

Pfizer Ireland Pharmaceuticals, a pharmaceutical company, filed an application for preliminary discovery against Samsung Bioepis AU Pty Ltd, a competitor in the biologics market, seeking disclosure of certain documents. The application was contested by Samsung Bioepis, and the matter was heard in the Federal Court of Australia. The primary focus of the case was the interpretation and application of the Federal Court Rules 2011, specifically concerning costs orders and the principles of confidentiality in preliminary discovery proceedings.

The court was required to decide several legal issues, including the appropriate exercise of discretion in making costs orders under section 43(2) of the Federal Court of Australia Act 1976, and the principles to be applied when determining whether to impose restrictions on the disclosure of confidential information during preliminary discovery. The court also needed to consider whether a contingent costs order was appropriate given the substantial success of Pfizer Ireland Pharmaceuticals in the application, despite it being contested.

The court exercised its discretion judiciously, taking into account the substantial success of Pfizer Ireland Pharmaceuticals in the application, which was contested by Samsung Bioepis. The court determined that a contingent costs order was not appropriate and instead awarded Pfizer Ireland Pharmaceuticals 50% of its costs. The court emphasised the need for confidentiality in preliminary discovery proceedings and imposed restrictions on the disclosure of certain information to protect the interests of both parties. The court outlined a process for the submission of costs, allowing both parties to provide written submissions and potentially respond to each other, before deciding whether to proceed to a hearing.

The court's orders included a timeline for the submission of written costs submissions and a procedure for determining the costs of the application. If no party filed written submissions in accordance with the specified timeline, certain orders would be made, and the question of costs would be addressed in separate orders. The court's approach ensured a balanced consideration of the interests of both parties while maintaining the confidentiality required in such proceedings.

Orders

Orders of the court

1. If either party desires to make a separate submission as to costs of the 3 April 2019 application, they must file and serve a written submission of no more than 4 pages within 7 days of these orders.

2. The other party may respond by filing and serving a written submission of no longer than 4 pages within 7 days thereafter.

3. Any reply submission of no more than 2 pages to be filed within 7 days thereafter.

4. The application will then be determined on the papers unless either party indicates a desire for a hearing.

5. If no party files written submissions in accordance with Order 1, Orders in accordance with those set out in Annexure A (and accompanying Annexure 1) will be made and the words “including the costs of the application of 3 April 2019” will be added to Order 19. If additional costs submissions are made, Orders in accordance with Annexure A (and accompanying Annexure 1) will be made 7 days after these Orders, and the question of costs of the 3 April 2019 application will be addressed in separate Orders.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established